226 related articles for article (PubMed ID: 34581310)
1. ANGPTL3 as therapeutic target.
Kersten S
Curr Opin Lipidol; 2021 Dec; 32(6):335-341. PubMed ID: 34581310
[TBL] [Abstract][Full Text] [Related]
2. New insights into ANGPLT3 in controlling lipoprotein metabolism and risk of cardiovascular diseases.
Su X; Peng DQ
Lipids Health Dis; 2018 Jan; 17(1):12. PubMed ID: 29334984
[TBL] [Abstract][Full Text] [Related]
3. Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: New therapeutic approaches for the treatment of atherogenic dyslipidemia.
Ruscica M; Zimetti F; Adorni MP; Sirtori CR; Lupo MG; Ferri N
Pharmacol Res; 2020 Mar; 153():104653. PubMed ID: 31931117
[TBL] [Abstract][Full Text] [Related]
4. Genetic Mimicry Analysis Reveals the Specific Lipases Targeted by the ANGPTL3-ANGPTL8 Complex and ANGPTL4.
Landfors F; Chorell E; Kersten S
J Lipid Res; 2023 Jan; 64(1):100313. PubMed ID: 36372100
[TBL] [Abstract][Full Text] [Related]
5. Angiopoietin-Like Protein 3 (ANGPTL3) Modulates Lipoprotein Metabolism and Dyslipidemia.
Chen PY; Gao WY; Liou JW; Lin CY; Wu MJ; Yen JH
Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34298929
[TBL] [Abstract][Full Text] [Related]
6. ANGPTL3 as a Drug Target in Hyperlipidemia and Atherosclerosis.
Mohamed F; Mansfield BS; Raal FJ
Curr Atheroscler Rep; 2022 Dec; 24(12):959-967. PubMed ID: 36367663
[TBL] [Abstract][Full Text] [Related]
7. Drugs that Mimic the Effect of Gene Mutations for the Prevention or the Treatment of Atherosclerotic Disease: From PCSK9 Inhibition to ANGPTL3 Inactivation.
Athyros VG; Katsiki N; Dimakopoulou A; Patoulias D; Alataki S; Doumas M
Curr Pharm Des; 2018; 24(31):3638-3646. PubMed ID: 30306859
[TBL] [Abstract][Full Text] [Related]
8. Angiopoietin-like 3 in lipoprotein metabolism.
Kersten S
Nat Rev Endocrinol; 2017 Dec; 13(12):731-739. PubMed ID: 28984319
[TBL] [Abstract][Full Text] [Related]
9. Triglyceride-rich lipoproteins, apolipoprotein C-III, angiopoietin-like protein 3, and cardiovascular events in older adults: Atherosclerosis Risk in Communities (ARIC) study.
Hussain A; Sun C; Selvin E; Nambi V; Coresh J; Jia X; Ballantyne CM; Hoogeveen RC
Eur J Prev Cardiol; 2022 Mar; 29(2):e53-e64. PubMed ID: 33580780
[TBL] [Abstract][Full Text] [Related]
10. Relationship between Serum Angiopoietin-like Proteins 3 and 8 and Atherogenic Lipid Biomarkers in Non-Diabetic Adults Depends on Gender and Obesity.
Murawska K; Krintus M; Kuligowska-Prusinska M; Szternel L; Stefanska A; Sypniewska G
Nutrients; 2021 Nov; 13(12):. PubMed ID: 34959891
[TBL] [Abstract][Full Text] [Related]
11. New insights into angiopoietin-like proteins in lipid metabolism and cardiovascular disease risk.
Kersten S
Curr Opin Lipidol; 2019 Jun; 30(3):205-211. PubMed ID: 30893111
[TBL] [Abstract][Full Text] [Related]
12. Cardiovascular and Metabolic Effects of ANGPTL3 Antisense Oligonucleotides.
Graham MJ; Lee RG; Brandt TA; Tai LJ; Fu W; Peralta R; Yu R; Hurh E; Paz E; McEvoy BW; Baker BF; Pham NC; Digenio A; Hughes SG; Geary RS; Witztum JL; Crooke RM; Tsimikas S
N Engl J Med; 2017 Jul; 377(3):222-232. PubMed ID: 28538111
[TBL] [Abstract][Full Text] [Related]
13. Genetic and Pharmacologic Inactivation of ANGPTL3 and Cardiovascular Disease.
Dewey FE; Gusarova V; Dunbar RL; O'Dushlaine C; Schurmann C; Gottesman O; McCarthy S; Van Hout CV; Bruse S; Dansky HM; Leader JB; Murray MF; Ritchie MD; Kirchner HL; Habegger L; Lopez A; Penn J; Zhao A; Shao W; Stahl N; Murphy AJ; Hamon S; Bouzelmat A; Zhang R; Shumel B; Pordy R; Gipe D; Herman GA; Sheu WHH; Lee IT; Liang KW; Guo X; Rotter JI; Chen YI; Kraus WE; Shah SH; Damrauer S; Small A; Rader DJ; Wulff AB; Nordestgaard BG; Tybjærg-Hansen A; van den Hoek AM; Princen HMG; Ledbetter DH; Carey DJ; Overton JD; Reid JG; Sasiela WJ; Banerjee P; Shuldiner AR; Borecki IB; Teslovich TM; Yancopoulos GD; Mellis SJ; Gromada J; Baras A
N Engl J Med; 2017 Jul; 377(3):211-221. PubMed ID: 28538136
[TBL] [Abstract][Full Text] [Related]
14. ANGPTL8 promotes the ability of ANGPTL3 to bind and inhibit lipoprotein lipase.
Chi X; Britt EC; Shows HW; Hjelmaas AJ; Shetty SK; Cushing EM; Li W; Dou A; Zhang R; Davies BSJ
Mol Metab; 2017 Oct; 6(10):1137-1149. PubMed ID: 29031715
[TBL] [Abstract][Full Text] [Related]
15. Regulation of lipoprotein metabolism by ANGPTL3, ANGPTL4, and ANGPTL8.
Sylvers-Davie KL; Davies BSJ
Am J Physiol Endocrinol Metab; 2021 Oct; 321(4):E493-E508. PubMed ID: 34338039
[TBL] [Abstract][Full Text] [Related]
16. ANGPTL3 and Apolipoprotein C-III as Novel Lipid-Lowering Targets.
Akoumianakis I; Zvintzou E; Kypreos K; Filippatos TD
Curr Atheroscler Rep; 2021 Mar; 23(5):20. PubMed ID: 33694000
[TBL] [Abstract][Full Text] [Related]
17. Angiopoietin-like protein 8: a multifaceted protein instrumental in regulating triglyceride metabolism.
Wen Y; Chen YQ; Konrad RJ
Curr Opin Lipidol; 2024 Apr; 35(2):58-65. PubMed ID: 37962908
[TBL] [Abstract][Full Text] [Related]
18. An anti-ANGPTL3/8 antibody decreases circulating triglycerides by binding to a LPL-inhibitory leucine zipper-like motif.
Balasubramaniam D; Schroeder O; Russell AM; Fitchett JR; Austin AK; Beyer TP; Chen YQ; Day JW; Ehsani M; Heng AR; Zhen EY; Davies J; Glaesner W; Jones BE; Siegel RW; Qian YW; Konrad RJ
J Lipid Res; 2022 May; 63(5):100198. PubMed ID: 35307397
[TBL] [Abstract][Full Text] [Related]
19. Angiopoietin-like 3 inhibition of endothelial lipase is not modulated by angiopoietin-like 8.
Sylvers-Davie KL; Segura-Roman A; Salvi AM; Schache KJ; Davies BSJ
J Lipid Res; 2021; 62():100112. PubMed ID: 34461133
[TBL] [Abstract][Full Text] [Related]
20. ANGPTL3 inhibition, dyslipidemia, and cardiovascular diseases.
Luo F; Das A; Khetarpal SA; Fang Z; Zelniker TA; Rosenson RS; Qamar A
Trends Cardiovasc Med; 2024 May; 34(4):215-222. PubMed ID: 36746257
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]